These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 38309427)
1. PDGF-D Is Dispensable for the Development and Progression of Murine Alport Syndrome. Firat EAM; Buhl EM; Bouteldja N; Smeets B; Eriksson U; Boor P; Klinkhammer BM Am J Pathol; 2024 May; 194(5):641-655. PubMed ID: 38309427 [TBL] [Abstract][Full Text] [Related]
2. A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome. Widjaja AA; Shekeran SG; Adami E; Ting JGW; Tan J; Viswanathan S; Lim SY; Tan PH; Hübner N; Coffman T; Cook SA J Am Soc Nephrol; 2022 Apr; 33(4):718-730. PubMed ID: 35140116 [TBL] [Abstract][Full Text] [Related]
4. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Gross O; Beirowski B; Koepke ML; Kuck J; Reiner M; Addicks K; Smyth N; Schulze-Lohoff E; Weber M Kidney Int; 2003 Feb; 63(2):438-46. PubMed ID: 12631109 [TBL] [Abstract][Full Text] [Related]
5. Albumin contributes to kidney disease progression in Alport syndrome. Jarad G; Knutsen RH; Mecham RP; Miner JH Am J Physiol Renal Physiol; 2016 Jul; 311(1):F120-30. PubMed ID: 27147675 [TBL] [Abstract][Full Text] [Related]
6. Identification of platelet-derived growth factor C as a mediator of both renal fibrosis and hypertension. van Roeyen CRC; Martin IV; Drescher A; Schuett KA; Hermert D; Raffetseder U; Otten S; Buhl EM; Braun GS; Kuppe C; Liehn E; Boor P; Weiskirchen R; Eriksson U; Gross O; Eitner F; Floege J; Ostendorf T Kidney Int; 2019 May; 95(5):1103-1119. PubMed ID: 30827511 [TBL] [Abstract][Full Text] [Related]
7. CG200745, a Novel HDAC Inhibitor, Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome. Suh SH; Choi HS; Kim CS; Kim IJ; Cha H; Cho JM; Ma SK; Kim SW; Bae EH Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098220 [TBL] [Abstract][Full Text] [Related]
9. Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. Gross O; Girgert R; Beirowski B; Kretzler M; Kang HG; Kruegel J; Miosge N; Busse AC; Segerer S; Vogel WF; Müller GA; Weber M Matrix Biol; 2010 Jun; 29(5):346-56. PubMed ID: 20307660 [TBL] [Abstract][Full Text] [Related]
10. Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2beta1 delays kidney fibrosis in COL4A3 knockout mice. Rubel D; Frese J; Martin M; Leibnitz A; Girgert R; Miosge N; Eckes B; Müller GA; Gross O Matrix Biol; 2014 Feb; 34():13-21. PubMed ID: 24480069 [TBL] [Abstract][Full Text] [Related]
11. Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Koepke ML; Weber M; Schulze-Lohoff E; Beirowski B; Segerer S; Gross O Nephrol Dial Transplant; 2007 Apr; 22(4):1062-9. PubMed ID: 17287218 [TBL] [Abstract][Full Text] [Related]
12. Olmesartan Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome by Suppressing Tubular Expression of TGFβ. Suh SH; Choi HS; Kim CS; Kim IJ; Ma SK; Scholey JW; Kim SW; Bae EH Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31390839 [TBL] [Abstract][Full Text] [Related]
13. Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis. Mitrofanova A; Molina J; Varona Santos J; Guzman J; Morales XA; Ducasa GM; Bryn J; Sloan A; Volosenco I; Kim JJ; Ge M; Mallela SK; Kretzler M; Eddy S; Martini S; Wahl P; Pastori S; Mendez AJ; Burke GW; Merscher S; Fornoni A Kidney Int; 2018 Dec; 94(6):1151-1159. PubMed ID: 30301568 [TBL] [Abstract][Full Text] [Related]
14. A human-mouse chimera of the alpha3alpha4alpha5(IV) collagen protomer rescues the renal phenotype in Col4a3-/- Alport mice. Heidet L; Borza DB; Jouin M; Sich M; Mattei MG; Sado Y; Hudson BG; Hastie N; Antignac C; Gubler MC Am J Pathol; 2003 Oct; 163(4):1633-44. PubMed ID: 14507670 [TBL] [Abstract][Full Text] [Related]
16. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. Tanaka M; Asada M; Higashi AY; Nakamura J; Oguchi A; Tomita M; Yamada S; Asada N; Takase M; Okuda T; Kawachi H; Economides AN; Robertson E; Takahashi S; Sakurai T; Goldschmeding R; Muso E; Fukatsu A; Kita T; Yanagita M J Clin Invest; 2010 Mar; 120(3):768-77. PubMed ID: 20197625 [TBL] [Abstract][Full Text] [Related]
17. COL4A3 mutation is an independent risk factor for poor prognosis in children with Alport syndrome. Ozdemir G; Gulhan B; Atayar E; Saygılı S; Soylemezoglu O; Ozcakar ZB; Eroglu FK; Candan C; Demir BK; Soylu A; Yüksel S; Alpay H; Agbas A; Duzova A; Hayran M; Ozaltin F; Topaloglu R Pediatr Nephrol; 2020 Oct; 35(10):1941-1952. PubMed ID: 32394188 [TBL] [Abstract][Full Text] [Related]
18. Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice. Steenhard BM; Vanacore R; Friedman D; Zelenchuk A; Stroganova L; Isom K; St John PL; Hudson BG; Abrahamson DR PLoS One; 2012; 7(12):e50745. PubMed ID: 23236390 [TBL] [Abstract][Full Text] [Related]
19. Loss of alpha3/alpha4(IV) collagen from the glomerular basement membrane induces a strain-dependent isoform switch to alpha5alpha6(IV) collagen associated with longer renal survival in Col4a3-/- Alport mice. Kang JS; Wang XP; Miner JH; Morello R; Sado Y; Abrahamson DR; Borza DB J Am Soc Nephrol; 2006 Jul; 17(7):1962-9. PubMed ID: 16769745 [TBL] [Abstract][Full Text] [Related]
20. Role of platelet-derived growth factor-CC in capillary rarefaction in renal fibrosis. Boor P; Bábíčková J; Steegh F; Hautvast P; Martin IV; Djudjaj S; Nakagawa T; Ehling J; Gremse F; Bücher E; Eriksson U; van Roeyen CR; Eitner F; Lammers T; Floege J; Peutz-Kootstra CJ; Ostendorf T Am J Pathol; 2015 Aug; 185(8):2132-42. PubMed ID: 26216283 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]